Page last updated: 2024-08-23

lithium and Tauopathies

lithium has been researched along with Tauopathies in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colton, CA; Everhart, A; Sudduth, TL; Wilcock, DM; Wilson, JG1
Loy, R; Tariot, PN1
Bhat, R; Burns, M; Dickson, D; Duff, K; Feinstein, B; Gaynor, K; Krishnamurthy, P; LaFrancois, J; Lewis, J; Meyerson, J; Noble, W; Olm, V; Planel, E; Suleman, F; Wang, L; Wen, Y; Zehr, C1
Hamamura, T; Ishihara, T; Kugo, A; Kuroda, S; Lee, VM; Nakashima, H; Oshima, E; Suguimoto, P; Terada, S; Trojanowski, JQ; Yokota, O1
Borghgraef, P; Croes, S; Devijver, H; Dewachter, I; Jaworski, T; Kremer, A; Muyllaert, D; Van Leuven, F1

Reviews

1 review(s) available for lithium and Tauopathies

ArticleYear
Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
    Genes, brain, and behavior, 2008, Volume: 7 Suppl 1

    Topics: Alzheimer Disease; Amyloid; Animals; Disease Models, Animal; Glycogen Synthase Kinase 3; Humans; Isoenzymes; Lithium; Mice; Mice, Transgenic; Phosphorylation; tau Proteins; Tauopathies

2008

Other Studies

4 other study(ies) available for lithium and Tauopathies

ArticleYear
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Humans; Inflammation; Learning; Lithium; Memory; Mice; Mice, Knockout; Mice, Transgenic; Nitric Oxide Synthase Type II; Phosphorylation; tau Proteins; Tauopathies; Treatment Outcome

2012
Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
    Journal of molecular neuroscience : MN, 2002, Volume: 19, Issue:3

    Topics: Alzheimer Disease; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium; Mice; Neuroprotective Agents; Phosphorylation; Research Design; Tauopathies; Valproic Acid

2002
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, May-10, Volume: 102, Issue:19

    Topics: Animals; Disease Progression; Enzyme Inhibitors; Epitopes; Glycogen Synthase Kinase 3; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Lithium; Lithium Chloride; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Phosphorylation; tau Proteins; Tauopathies

2005
Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Acta neuropathologica, 2005, Volume: 110, Issue:6

    Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Glycogen Synthase Kinase 3; Humans; Immunohistochemistry; Lithium; Mice; Mice, Transgenic; Microscopy, Confocal; Phosphorylation; tau Proteins; Tauopathies; Time Factors; Ubiquitin

2005